More US Positions Go As Daiichi Sankyo Refocuses
Executive Summary
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
You may also be interested in...
Daiichi's Quizartinib Looks To Join Novartis' Rydapt In AML
Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.
After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?
Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.
Endgame For Singh Bros As India’s Top Court Upholds $550m Daiichi Arbitration Panel Award
Tycoons Malvinder and Shivinder Singh have exhausted Indian legal avenues in their fight against enforcement of a Singapore arbitration panel order to pay $550m to Japanese firm Daiichi Sankyo and now must decide whether to take their battle to a Singapore court.